Developer docs
API playgroundTry for free, no card

Search company profiles

Apollo Therapeutics

Full company profile

uuid0000eua

Namestring
Apollo Therapeutics
Legal namestring
Apollo Therapeutics Ltd.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Apollo Therapeutics is a portfolio biopharmaceutical company founded in 2015 and headquartered in Cambridge, United Kingdom, that translates breakthroughs in biology and basic medical research into innovative new medicines. The company operates a scalable R&D platform built on partnerships with six of the UK's leading universities and research institutes — including the University of Cambridge, Imperial College London, King's College London, and UCL — providing continuous access to upstream scientific discovery. Its pipeline spans oncology, immunology, and rare diseases and currently comprises over 20 active therapeutic programs, of which five to six are in clinical-stage development; the portfolio is deliberately structured to provide uncorrelated risk across multiple programs.

The company augments its university-derived pipeline through in-licensing and acquisition of clinical-stage programs where its internal discovery work creates unique synergies. Its core "product" is the therapeutic pipeline itself rather than any single molecule; Apollo is pre-revenue with no approved or commercialized medicines, and pricing is therefore not yet applicable. Future revenue is expected to be generated through licensing deals and royalties with major pharmaceutical partners or, eventually, through direct commercialization of approved therapies.

Apollo is backed by specialist healthcare investors led by Patient Square Capital, with additional participation from Rock Springs Capital, M&G plc, US public pension plans, Reimagined Ventures, UCL Technology Fund, and IP Group. Total disclosed funding exceeds $400 million, anchored by a $145 million Series B in June 2021 and a $260 million Series C closed in two tranches in September and December 2023. The company maintains UK R&D operations in Cambridge and Oxford alongside US offices in Boston and Chicago, and has appointed Timothy P. Walbert — former Chairman, President and CEO of Horizon Therapeutics through its approximately $28.3 billion acquisition by Amgen in 2023 — as Chairman to support late-stage clinical execution and eventual commercialization.

Short descriptiontext

Apollo Therapeutics is a UK-based portfolio biopharmaceutical company that translates academic research breakthroughs into new medicines across oncology, immunology, and rare diseases. It operates a diversified pipeline of over 20 programs built on partnerships with six leading UK universities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical development, drug discovery platform, clinical-stage therapeutics, oncology immunology pipeline, rare disease medicines
Industry2 codes
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue biopharmaceutical company developing a diversified portfolio of therapeutic programs in oncology, immunology, and rare diseases. Revenue will be generated through eventual commercialization of developed medicines, either directly or through partnerships with major pharmaceutical companies.

apollotx.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Apollo Therapeutics is a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. It operates a scalable R&D platform with access to science from six of the world's leading universities and research institutes, advancing over 20 active therapeutic programs (six in clinical development) across oncology, immunology, and rare diseases. The company supplements internal R&D with in-licensing and acquisition of clinical-stage programs where it has unique insights and synergies, and ultimately intends to commercialize medicines through partnerships with major pharmaceutical companies or directly.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Apollo Therapeutics operates as a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. The company maintains a scalable R&D platform enabled by unprecedented access to research from six of the world's leading universities and research institutes. Its core product is the therapeutic programs pipeline comprising over 20 active programs, with six in clinical development. The portfolio model provides diversified novel therapeutics with uncorrelated risk, augmented by in-licensing and acquisition of clinical-stage programs where unique insights and synergies exist.

Product and service1 record
1Therapeutic Programs Pipeline
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Research institution partner for drug discovery and development programs, part of the six universities providing breakthrough science access.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Research institution partner for drug discovery and development programs, part of the six universities providing breakthrough science access.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Research institution partner for drug discovery and development activities, part of university research collaboration network.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PureTech Health is a clinical-stage biotherapeutics company that translates academic and scientific research into medicines through a portfolio of programs — closely mirroring Apollo's model of sourcing programs from leading research institutions and advancing them via a centralized R&D platform.

TypeDirect peer
Description

Roivant Sciences operates a portfolio model that in-licenses and develops therapeutic programs across multiple therapeutic areas, leveraging a hub-and-spoke structure to advance diverse assets — highly analogous to Apollo's diversified portfolio approach.

TypeDirect peer
Description

BridgeBio Pharma is a portfolio biopharma building multiple drugs for genetic diseases and rare conditions across separate subsidiaries. Apollo shares the portfolio strategy and rare disease therapeutic focus, though Apollo's pipeline spans oncology and immunology more broadly.

TypeDirect peer
Description

Centessa Pharmaceuticals is a clinical-stage pharmaceutical company with a portfolio of multiple asset-centric programs operated under a unified R&D infrastructure — the same capital allocation and shared platform philosophy Apollo applies to its 20+ programs.

TypeEmerging player
Description

Medicxi is a life sciences-focused investment firm that develops and owns therapeutic programs originating from European academic research, sharing Apollo's translational academic-to-industry pipeline approach and European biotech origins.

TypeBroad incumbent
Description

Recursion is a clinical-stage biotech using an AI-enabled platform to advance a portfolio of discovered and in-licensed therapeutic programs. While more technology-centric, it competes in similar early-stage drug discovery with a portfolio-style pipeline philosophy.

TypeBroad incumbent
Description

Exscientia is an AI-driven pharmatech company that partners with pharma to discover and develop small molecule therapeutics across multiple programs — adjacent to Apollo in building diversified pipelines, though enabled by computational rather than academic-sourced discovery.

TypeBroad incumbent
Description

Schrödinger operates a computational drug discovery platform and advances an internal pipeline of wholly-owned and partnered programs. Comparable to Apollo as a portfolio biopharma with differentiated discovery capabilities, though based on physics-based simulation rather than university partnerships.

TypeDirect peer
Description

Nimbus Therapeutics is a clinical-stage biotech that designs and develops a portfolio of small molecule therapeutics across multiple disease areas using structure-based drug design — sharing Apollo's strategy of advancing multiple therapeutic programs in parallel with deep R&D capabilities.

10Isomorphic Labs
TypeEmerging player
Description

Isomorphic Labs is an Alphabet-backed drug discovery company applying AI to accelerate therapeutic development, with a portfolio approach to multiple programs. It overlaps with Apollo's translational model of building a diversified pipeline, but via AI-driven rather than academic-sourced discovery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apollo Therapeutics

Biopharmaceutical Drug Developmentapollotherapeutics.com

Apollo Therapeutics is a UK-based portfolio biopharmaceutical company that translates academic research breakthroughs into new medicines across oncology, immunology, and rare diseases. It operates a diversified pipeline of over 20 programs built on partnerships with six leading UK universities.

What Apollo Therapeutics does

Apollo Therapeutics is a portfolio biopharmaceutical company founded in 2015 and headquartered in Cambridge, United Kingdom, that translates breakthroughs in biology and basic medical research into innovative new medicines. The company operates a scalable R&D platform built on partnerships with six of the UK's leading universities and research institutes — including the University of Cambridge, Imperial College London, King's College London, and UCL — providing continuous access to upstream scientific discovery. Its pipeline spans oncology, immunology, and rare diseases and currently comprises over 20 active therapeutic programs, of which five to six are in clinical-stage development; the portfolio is deliberately structured to provide uncorrelated risk across multiple programs.

The company augments its university-derived pipeline through in-licensing and acquisition of clinical-stage programs where its internal discovery work creates unique synergies. Its core "product" is the therapeutic pipeline itself rather than any single molecule; Apollo is pre-revenue with no approved or commercialized medicines, and pricing is therefore not yet applicable. Future revenue is expected to be generated through licensing deals and royalties with major pharmaceutical partners or, eventually, through direct commercialization of approved therapies.

Apollo is backed by specialist healthcare investors led by Patient Square Capital, with additional participation from Rock Springs Capital, M&G plc, US public pension plans, Reimagined Ventures, UCL Technology Fund, and IP Group. Total disclosed funding exceeds $400 million, anchored by a $145 million Series B in June 2021 and a $260 million Series C closed in two tranches in September and December 2023. The company maintains UK R&D operations in Cambridge and Oxford alongside US offices in Boston and Chicago, and has appointed Timothy P. Walbert — former Chairman, President and CEO of Horizon Therapeutics through its approximately $28.3 billion acquisition by Amgen in 2023 — as Chairman to support late-stage clinical execution and eventual commercialization.

Apollo Therapeutics firmographics

Firmographics
Name
Apollo Therapeutics
Legal name
Apollo Therapeutics Ltd.
Website
https://apollotherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Apollo Therapeutics is a UK-based portfolio biopharmaceutical company that translates academic research breakthroughs into new medicines across oncology, immunology, and rare diseases. It operates a diversified pipeline of over 20 programs built on partnerships with six leading UK universities.
Ownership category
akta.pro rank

Apollo Therapeutics industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biopharmaceutical development
  • Drug discovery platform
  • Clinical-stage therapeutics
  • Oncology immunology pipeline
  • Rare disease medicines

Where Apollo Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Apollo Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing a diversified portfolio of therapeutic programs in oncology, immunology, and rare diseases. Revenue will be generated through eventual commercialization of developed medicines, either directly or through partnerships with major pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Apollo Therapeutics product offering

Product offering

Core offering

Apollo Therapeutics is a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. It operates a scalable R&D platform with access to science from six of the world's leading universities and research institutes, advancing over 20 active therapeutic programs (six in clinical development) across oncology, immunology, and rare diseases. The company supplements internal R&D with in-licensing and acquisition of clinical-stage programs where it has unique insights and synergies, and ultimately intends to commercialize medicines through partnerships with major pharmaceutical companies or directly.

Product overview

Apollo Therapeutics operates as a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. The company maintains a scalable R&D platform enabled by unprecedented access to research from six of the world's leading universities and research institutes. Its core product is the therapeutic programs pipeline comprising over 20 active programs, with six in clinical development. The portfolio model provides diversified novel therapeutics with uncorrelated risk, augmented by in-licensing and acquisition of clinical-stage programs where unique insights and synergies exist.

Differentiator

Problem solved

Functional benefit

Products and services

  • Therapeutic Programs Pipeline

Companies that use Apollo Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Apollo Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Apollo Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • University of CambridgecoreStrategic or Co-development Partner · 1 September 2023Research institution partner for drug discovery and development programs, part of the six universities providing breakthrough science access.
  • Imperial College LondoncoreStrategic or Co-development Partner · 1 September 2023Research institution partner for drug discovery and development programs, part of the six universities providing breakthrough science access.
  • King's College LondoncoreStrategic or Co-development Partner · 1 September 2023Research institution partner for drug discovery and development activities, part of university research collaboration network.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Apollo Therapeutics competitors and assessment

Company assessment

Direct peers

  • PureTech Health: PureTech Health is a clinical-stage biotherapeutics company that translates academic and scientific research into medicines through a portfolio of programs — closely mirroring Apollo's model of sourcing programs from leading research institutions and advancing them via a centralized R&D platform.
  • Roivant Sciences: Roivant Sciences operates a portfolio model that in-licenses and develops therapeutic programs across multiple therapeutic areas, leveraging a hub-and-spoke structure to advance diverse assets — highly analogous to Apollo's diversified portfolio approach.
  • BridgeBio Pharma: BridgeBio Pharma is a portfolio biopharma building multiple drugs for genetic diseases and rare conditions across separate subsidiaries. Apollo shares the portfolio strategy and rare disease therapeutic focus, though Apollo's pipeline spans oncology and immunology more broadly.
  • Centessa Pharmaceuticals: Centessa Pharmaceuticals is a clinical-stage pharmaceutical company with a portfolio of multiple asset-centric programs operated under a unified R&D infrastructure — the same capital allocation and shared platform philosophy Apollo applies to its 20+ programs.
  • Nimbus Therapeutics: Nimbus Therapeutics is a clinical-stage biotech that designs and develops a portfolio of small molecule therapeutics across multiple disease areas using structure-based drug design — sharing Apollo's strategy of advancing multiple therapeutic programs in parallel with deep R&D capabilities.

Emerging players

  • Medicxi: Medicxi is a life sciences-focused investment firm that develops and owns therapeutic programs originating from European academic research, sharing Apollo's translational academic-to-industry pipeline approach and European biotech origins.
  • Isomorphic Labs: Isomorphic Labs is an Alphabet-backed drug discovery company applying AI to accelerate therapeutic development, with a portfolio approach to multiple programs. It overlaps with Apollo's translational model of building a diversified pipeline, but via AI-driven rather than academic-sourced discovery.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion is a clinical-stage biotech using an AI-enabled platform to advance a portfolio of discovered and in-licensed therapeutic programs. While more technology-centric, it competes in similar early-stage drug discovery with a portfolio-style pipeline philosophy.
  • Exscientia: Exscientia is an AI-driven pharmatech company that partners with pharma to discover and develop small molecule therapeutics across multiple programs — adjacent to Apollo in building diversified pipelines, though enabled by computational rather than academic-sourced discovery.
  • Schrödinger: Schrödinger operates a computational drug discovery platform and advances an internal pipeline of wholly-owned and partnered programs. Comparable to Apollo as a portfolio biopharma with differentiated discovery capabilities, though based on physics-based simulation rather than university partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Apollo Therapeutics social profiles

Digital presence

Apollo Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apollo Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Apollo Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apollo Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apollo Therapeutics

What does Apollo Therapeutics do?

Apollo Therapeutics is a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. It operates a scalable R&D platform with access to science from six of the world's leading universities and research institutes, advancing over 20 active therapeutic programs (six in clinical development) across oncology, immunology, and rare diseases. The company supplements internal R&D with in-licensing and acquisition of clinical-stage programs where it has unique insights and synergies, and ultimately intends to commercialize medicines through partnerships with major pharmaceutical companies or directly.

Is Apollo Therapeutics a public or private company?

Apollo Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Apollo Therapeutics founded?

Apollo Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Apollo Therapeutics based?

Apollo Therapeutics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Apollo Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Apollo Therapeutics's main competitors?

Direct peers on record are PureTech Health, Roivant Sciences, BridgeBio Pharma, Centessa Pharmaceuticals and Nimbus Therapeutics. Emerging players are Medicxi and Isomorphic Labs. Broad incumbents are Recursion Pharmaceuticals, Exscientia and Schrödinger.

Does Apollo Therapeutics have an API?

No public API is recorded for Apollo Therapeutics.

What industry is Apollo Therapeutics in?

Apollo Therapeutics's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialApollo Therapeutics Announces Science Translational Medicine Publication Supporting APL-9796 As A Potential Disease-Modifying Approach For Pulmonary HypertensionApollo Therapeutics published a Science Translational Medicine paper on APL-9796, a ZIP12 antagonist for pulmonary hypertension. The antibody was well tolerated in a Phase 1 trial and is now in Phase 2 (ViTAL-PH). The trial uses CardioMEMS telemetry to assess hemodynamic effects.Mirage NewsPromising Results in Early Common Cold Vaccine TrialsApollo Therapeutics and Imperial College London announced that enrolment and dosing in a randomised, placebo-controlled Phase 1 trial of rhinovirus vaccine candidate APL-10456 has completed. Initial results from 144 healthy participants showed the vaccine was well tolerated and induced immune responses against all three major rhinovirus species. A two-dose regimen in adults over 55 is planned, with further data expected in Q4 2026.The IndependentEarly trials for vaccine for common cold are ‘encouraging’, scientists sayScientists from Imperial College London and Apollo Therapeutics reported encouraging results from an early trial of the APL-10456 vaccine, which induced immunity against three main rhinovirus species in 144 healthy volunteers aged 18 to 54. The trial, which found the vaccine well tolerated, will move to a second phase with results expected by year-end, and a COPD study is planned for 2027.AijournVirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataVirTus Respiratory Research Ltd, a CRO co-led by Imperial College London investigators, said it supported Apollo Therapeutics' APL-10456, an adjuvanted recombinant protein subunit vaccine for rhinovirus-driven COPD and asthma exacerbations, through more than 20 preclinical studies. Apollo reported that Phase 1 enrolment and dosing of 144 healthy participants completed, with Part A data showing a single dose was well tolerated and highly immunogenic.Financial PostVirTus Respiratory Research Supports Development of Apollo Therapeutics' APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataVirTus Respiratory Research, a respiratory CRO co-founded by Imperial College London investigators, announced its role in preclinical development of Apollo Therapeutics' APL-10456, a first-in-class adjuvanted recombinant protein subunit vaccine for rhinovirus-driven COPD and asthma exacerbations. VirTus conducted over 20 preclinical studies, including cross-species immunogenicity and rhinovirus infection models. Apollo's Phase 1 trial of 144 healthy participants completed, with Part A data showing a single dose was well tolerated and highly immunogenic.FinancialContent Business PageVirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataVirTus Respiratory Research Ltd, a CRO co-led by Imperial College London investigators, said it supported over five years of preclinical development of Apollo Therapeutics' APL-10456, conducting more than 20 studies including cross-species immunogenicity and rhinovirus efficacy models. Apollo's Phase 1 trial of 144 healthy participants completed, with Part A data showing a single dose was well tolerated and highly immunogenic.MorningstarVirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataVirTus Respiratory Research supported Apollo Therapeutics' APL-10456 vaccine through over 20 preclinical studies, including cross-species immunogenicity testing. The Phase 1 trial of 144 participants showed the vaccine was well tolerated and highly immunogenic, inducing cross-reactive responses against all three rhinovirus species.BioSpaceVirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataVirTus Respiratory Research supported Apollo Therapeutics' APL-10456 vaccine through preclinical studies, and Phase 1 data showed the vaccine was well tolerated and highly immunogenic. The single-dose vaccine induced cross-reactive immune responses against all three rhinovirus species, consistent with preclinical findings.European BiotechnologyApollo vaccine triggers broad rhinovirus immunity in Phase 1Apollo Therapeutics reported Phase 1 data showing its rhinovirus vaccine APL-10456 induced immune responses against all three rhinovirus species in healthy adults. The trial enrolled 144 volunteers, with no serious adverse events, and results from the older-age cohort are expected in Q4 2026. Apollo plans a Phase 2 trial in COPD patients in 2027.citybizApollo Therapeutics Names Former Horizon CEO Timothy Walbert Chairman of the BoardApollo Therapeutics has appointed Timothy P. Walbert, former chairman, president and CEO of Horizon Therapeutics, as Chairman of its Board of Directors. Walbert joins Apollo with over 30 years of biopharmaceutical leadership experience, most notably having built and scaled Horizon Therapeutics from its founding in 2008 through its acquisition by Amgen in 2023 for approximately $28.3 billion. The appointment is intended to strengthen Apollo's board as the company advances five clinical-stage programs and prepares for later-stage clinical execution and eventual commercialization.